[625,000% Gain] – Are You Ready for the Next Altcoin Boom?

All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.

Andy Sassine Biography and Net Worth

Director of iCAD

Andy Sassine is currently, and has been since January 2019, the Chief Financial Officer at Arcturus Therapeutics. He also serves on the Board of Directors of Nasdaq listed ICAD Inc. ICAD Inc. is a leading provider of advanced image analysis, workflow solutions and radiation therapy for early detection and treatment of cancer. Mr. Sassine served in various positions at Fidelity Investments from 1999 to 2012, including, most recently as Portfolio Manager. Between 2005 and 2011, he managed the Fidelity Small Cap Stock Fund, the Fidelity International Small Cap Opportunities Fund and the Fidelity Advisor International Small Cap Opportunities Fund. Mr. Sassine joined Fidelity as a high yield research analyst, covering the Telecommunications, Satellite, Technology, Defense and Aerospace, and Restaurant Industries and in 2001, joined the international group as a research analyst covering small and mid-cap international stocks. Mr. Sassine has been a member of the Henry B. Tippie College of Business, University of Iowa Board of Advisors from 2009 to 2018. Mr. Sassine earned a Bachelor of Arts degree at the University of Iowa in 1987 and an MBA from the Wharton School at the University of Pennsylvania in 1993.

What is Andy Sassine's net worth?: The estimated net worth of Andy Sassine is at least $2.04 million as of September 8th, 2020. Mr. Sassine owns 1,324,882 shares of iCAD stock worth more than $2,040,186 as of November 21st. This net worth estimate does not reflect any other assets that Mr. Sassine may own. Learn More about Andy Sassine's net worth.
How do I contact Andy Sassine?: The corporate mailing address for Mr. Sassine and other iCAD executives is 98 SPIT BROOK ROAD SUITE 100, NASHUA NH, 03062. iCAD can also be reached via phone at (603) 882-5200 and via email at [email protected]. Learn More on Andy Sassine's contact information.
Has Andy Sassine been buying or selling shares of iCAD?: Andy Sassine has not been actively trading shares of iCAD within the last three months. Most recently, Andy Sassine sold 10,000 shares of the business's stock in a transaction on Monday, February 7th. The shares were sold at an average price of $5.26, for a transaction totalling $52,600.00. Learn More on Andy Sassine's trading history.
Who are iCAD's active insiders?: iCAD's insider roster includes Charles Carter (CFO), Jonathan Go (CTO), Timothy Irish (Director), Michael Klein (CEO), Andy Sassine (Director), Stacey Stevens (President), and Susan Wood (Director). Learn More on iCAD's active insiders.

Andy Sassine Insider Trading History at iCAD

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/7/2022	Sell	10,000	$5.26	$52,600.00
12/6/2021	Sell	10,000	$6.71	$67,100.00
11/8/2021	Sell	10,000	$10.89	$108,900.00
10/6/2021	Sell	10,000	$10.56	$105,600.00
9/13/2021	Sell	10,000	$11.09	$110,900.00
9/8/2020	Sell	10,000	$9.40	$94,000.00	1,324,882
7/13/2020	Sell	10,000	$9.53	$95,300.00	1,364,882

Andy Sassine Buying and Selling Activity at iCAD

iCAD Company Overview

iCAD, Inc. engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis. The company was formerly known as Howtek, Inc. and changed its name to iCAD, Inc. in June 2002. iCAD, Inc. was incorporated in 1984 and is headquartered in Nashua, New Hampshire.

Today's Range

Now: $1.54

$1.49

$1.55

50 Day Range

MA: $1.72

$1.39

$2.40

2 Week Range

Now: $1.54

$1.18

$2.65

Volume

99,864 shs

Average Volume

174,427 shs

Market Capitalization

$40.87 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.47